Relevant bibliographies by topics / Immunocheckpoint

Academic literature on the topic 'Immunocheckpoint'

Author: Grafiati
Published: 1 April 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Immunocheckpoint.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Immunocheckpoint"

1

Rizzo, Mimma, Matteo Santoni, and Camillo Porta. "Treatment sequencing strategies in metastatic renal cell carcinoma: A critical interpretation of available data." Journal of Onco-Nephrology 4, no. 3 (August 18, 2020): 153–64. http://dx.doi.org/10.1177/2399369320943609.

Full text
Abstract:
Therapeutic sequencing strategies for metastatic renal cell carcinoma have evolved significantly over time. For about 10 years, vascular endothelial growth factor receptor-targeted therapies and mammalian target of rapamycin inhibitors have been the standard of care. About 5 years ago an immunocheckpoint inhibitor, nivolumab, has opened new therapeutic perspectives. Recent clinical studies have confirmed the biological rationale of combining two immunocheckpoint inhibitors or vascular endothelial growth factor-targeted therapies plus immunocheckpoint inhibitors, demonstrating an improvement in clinical outcomes. We are still unable to recognize immunocheckpoint inhibitors responder patients from vascular endothelial growth factor-targeted therapies responder patients and, therefore, to quantify in a certain patient the benefits/harms ratio of upfront combination over sequence therapy in a certain patient. However, the metastatic renal cell carcinoma records of high-volume cancer centers could reveal the effectiveness and tolerability of combined treatments and indicate the potentially predictive factors and the management strategies in the real-world population.
APA, Harvard, Vancouver, ISO, and other styles
2

Singh, Navdeep, Sandeep Singh Lubana, George Constantinou, and Andrea N. Leaf. "Immunocheckpoint Inhibitor- (Nivolumab-) Associated Hypereosinophilia in Non-Small-Cell Lung Carcinoma." Case Reports in Oncological Medicine 2020 (May 15, 2020): 1–5. http://dx.doi.org/10.1155/2020/7492634.

Full text
Abstract:
Immunocheckpoint inhibitor (ICI) therapy has provided significant clinical improvements in the treatment of several malignancies. The purpose of this report is to increase awareness of hypereosinophilia associated with checkpoint inhibitors, a topic that has been rarely reported. Hypereosinophilia may need to be addressed especially if eosinophil counts increase to levels where hypereosinophilic visceral complications can occur. We are presenting a case of a 57-year-old male with hypereosinophilia that was seen in the setting of progression of metastatic non-small-cell lung cancer during and after nivolumab treatment.
APA, Harvard, Vancouver, ISO, and other styles
3

Borghaei, Hossein. "Emerging evidence of immunocheckpoint inhibitors in non-small cell lung cancer." Annals of Oncology 28 (October 2017): ix20. http://dx.doi.org/10.1093/annonc/mdx552.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Cazzato, Gerardo, Eliano Cascardi, Anna Colagrande, Teresa Lettini, Alessandra Filosa, Francesca Arezzo, Carmelo Lupo, et al. "T Cell Immunoglobulin and Mucin Domain 3 (TIM-3) in Cutaneous Melanoma: A Narrative Review." Cancers 15, no. 6 (March 10, 2023): 1697. http://dx.doi.org/10.3390/cancers15061697.

Full text
Abstract:
T cell immunoglobulin and mucin domain 3 (TIM-3) is an inhibitory immunocheckpoint that belongs to the TIM gene family. Monney et al. first discovered it about 20 years ago and linked it to some autoimmune diseases; subsequent studies have revealed that some tumours, including melanoma, have the capacity to produce inhibitory ligands that bind to these receptor checkpoints on tumour-specific immune cells. We conducted a literature search using PubMed, Web of Science (WoS), Scopus, Google Scholar, and Cochrane, searching for the following keywords: “T cell immunoglobulin and mucin-domain containing-3”, “TIM-3” and/or “Immunocheckpoint inhibitors” in combination with “malignant melanoma” or “human malignant melanoma” or “cutaneous melanoma”. The literature search initially turned up 117 documents, 23 of which were duplicates. After verifying eligibility and inclusion criteria, 17 publications were ultimately included. A growing body of scientific evidence considers TIM-3 a valid inhibitory immuno-checkpoint with a very interesting potential in the field of melanoma. However, other recent studies have discovered new roles for TIM-3 that seem almost to contradict previous findings in this regard. All this demonstrates how common and valid the concept of ‘pleiotropism’ is in the TME field, in that the same molecule can behave completely or partially differently depending on the cell type considered or on temporary conditions. Further studies, large case series, and a special focus on the immunophenotype of TIM-3 are absolutely necessary in order to explore this highly promising topic in the near future.
APA, Harvard, Vancouver, ISO, and other styles
5

Santoni, Matteo, Daniel Y. C. Heng, Gaetano Aurilio, Andrea Iozzelli, Lucilla Servi, Andrea Fabiani, Massimo Giannini, et al. "Combining Radiotherapy with Immunocheckpoint Inhibitors or CAR-T in Renal Cell Carcinoma." Current Drug Targets 21, no. 4 (March 2, 2020): 416–23. http://dx.doi.org/10.2174/1389450120666191017113051.

Full text
Abstract:
Radiotherapy is considered a second life in Renal Cell Carcinoma (RCC) patients, mainly due to the introduction of immune checkpoint inhibitors, such as anti-Programmed-death (PD)-1, alone or in combination with anti-Cytotoxic T-Lymphocyte Antigen (CTLA)-4. Several trials are investigating the efficacy/safety of immune checkpoint inhibitors in sequential or combined strategies with radiotherapy. Chimeric Antigen Receptor (CAR)-T cells therapy as a promising approach in cancer patients has opened the way to novel possibilities of integrating therapies. The identification of biomarkers of tumor response to these combinations represents a challenge in RCC, together with the research for the best partner for immunotherapy in metastatic patients. In this review we illustrated preclinical/clinical data on the integration of radiotherapy with immunocheckpoint inhibitors or CART cells in RCC.
APA, Harvard, Vancouver, ISO, and other styles
6

Mejías, Claudia, and Osmany Guirola. "Pharmacophore model of immunocheckpoint protein PD-L1 by cosolvent molecular dynamics simulations." Journal of Molecular Graphics and Modelling 91 (September 2019): 105–11. http://dx.doi.org/10.1016/j.jmgm.2019.06.001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ebata, T., T. Shimizu, S. Iizumi, T. Koyama, A. Shimomura, S. Iwasa, S. Kondo, et al. "Prognostic factors of patients received immunocheckpoint inhibitors in oncology phase 1 trials." Annals of Oncology 28 (November 2017): x40. http://dx.doi.org/10.1093/annonc/mdx658.004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Sonmez, Ozlem, Ozlem Nuray Sever, Basak Oyan, and Osman Gokhan Demir. "Immunotherapy releated cardiomyopathy." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e14601-e14601. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e14601.

Full text
Abstract:
e14601 Background: Side effects of immunotherapies also differ from classical cytoxic chemotherapy agents such as effects. Cardiomyopathy is a relatively rare complication. Studies have shown that the risk of developing myocarditis is higher when the ipilimumab / nivolumab combination is used than when the single agent nivolumab is used. ImmunoCheckpoint inhibitors are associated with an increase in immunologic response and immunosuppressives such as corticosteroids, TNF-alpha antagonists and mycophenolate acetate are used in treatment.In this study, we aimed to report cardiac toxicity in patients who treated with immune checkpoint inhibitors. Methods: Forty patients who were treated with immunocheckpoint inhibitors were screened retrospectively at two centers in Turkey between August 2015 and January 2017 . Results: Twenty-eight of the patients were male (70%), 12 were female (30%); The median age was 61 (32-81) years. 23 (57.5%) patients received nivolumab and 16 (40 %) patients received pembrolizumab and 1(2.5%) patient received pembrolizumab/ipilimumab combination. Seven of the cases had immuno-related side effects (17.5%).In two of our patients, after the second cure of the treatment, diffuse edema and shortness of breath due to heart failure was detected. Echocardiography revealed a low ejection fraction. Methylprednisolone was started by cessation of treatment. One week after the symptoms improved rapidly and control ejection fractions normalized. One of these patients was diagnosed with malignant melanoma and the other with RCC , they using pembrolizumab and nivolumab respectively. Conclusions: In conclusion, side effects that may occur may lead to fatal outcomes, while immunotherapy, which is increasingly used in oncology practice, may result in satisfactory success in treatment. Patients and their relatives should be adequately informed about side effects caused by these agents, complaints should be carefully evaluated and treatment should be started without spending time.
APA, Harvard, Vancouver, ISO, and other styles
9

Saigi, Maria, Juan J. Alburquerque-Bejar, and Montse Sanchez-Cespedes. "Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front." Oncogene 38, no. 31 (June 28, 2019): 5921–32. http://dx.doi.org/10.1038/s41388-019-0855-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Takamori, S., T. Komiya, and E. Powell. "P75.06 Survival Benefit From Immunocheckpoint Inhibitors in Stage IV Non-Small Cell Lung Cancer Patients With Brain Metastases." Journal of Thoracic Oncology 16, no. 3 (March 2021): S575—S576. http://dx.doi.org/10.1016/j.jtho.2021.01.1040.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Immunocheckpoint"

1

MONTESANO, Luigi. "Analysis of infiltrating γδ T cells in cutaneous melanoma: a hypothetic crosstalk for new immunotherapy." Doctoral thesis, Università degli Studi di Palermo, 2022. https://hdl.handle.net/10447/564105.

Full text
Abstract:
Introduction: Melanoma is one of the most frequently occurring skin cancer and remains an important cause of mortality mainly in Caucasian populations. In clinical practice, the standard treatment for localized melanoma is surgical resection but for metastatic melanoma, few treatments are available, where chemo and radio-therapies are rarely indicated. Immunotherapy has revolutionized the management of metastatic melanoma that, as in others tumors, uses your body's own immune system to help fight cancer. Therapies targeting the immune checkpoint molecules have achieved objective responses in melanoma. Several receptors and/or ligands, such as PDL1, PD-1 and CTLA-4, have been identified as important regulatory molecules but these therapies are not effective for a large number of patients. The importance of the immune response in the clinical outcome was correlated with increased number of tumor-infiltrating lymphocytes (TILs) in melanoma and in several other tumors. Many studies underline the role of γδ T lymphocytes in the anti-tumor surveillance with a marked cytotoxic effect towards tumor cells. We investigated the expression of some novel immune checkpoint molecules, such as TIM3 (T-cell immunoglobulin and mucin-domain containing-3), TIGIT (Tcell Ig and ITIM domain) and LAG3 (lymphocyte activation gene-3) on T lymphocytes. Material and Methods: From 2018 to 2021, 54 adult patients were enrolled in our study with clinical suspicion of melanoma, at the Plastic Surgery Department of the University Hospital in Palermo. A blood drawing (in a dry test tube) and a fragment (about 1 mm) of perilesional skin was taken before the tumoral excision. All bioptical samples were processed immediately through mechanical and enzymatic digestion. After the immunological cells were analysed by flow cytometry. We conducted also the immunofluorescence staining on tumoral samples and bioinformatics analysis through dataset online. Results: The analysis of the histological examination reports showed that in 75% of cases the diagnosis of suspected melanoma was confirmed. The infiltrating and circulating T lymphocytes analysis showed that the cell percentage was higher in peripheral blood than in peritumoral tissues in particular 5 on melanoma’s metastases. The study of the immunocheckpoint molecules expression (PD1, TIGIT, LAG3 and TIM3) showed higher values in the infiltrating compared to circulating T cells. In addition, a detailed analysis of these data in correlation with pathological stage of melanoma, showed that, on perilesional infiltrating T lymphocytes, PD-1 is more expressed in melanomas in situ, then decreasing from pt1a as pathological stage increases. TIM3, TIGIT and LAG3, were expressed in other stage. The circulating T lymphocytes investigation showed variable values for pathological stage, except TIGIT, whose values were higher in the ptis and pt1a. In the mestastases, all immunocheckpoints were more expressed, expecially LAG3. Furthermore, the bioinformatic analysis showed that immunotherapy with checkpoint inhibitors (anti-PD1, anti-CTL4 and anti- PD1/CTL4) caused an increase in memory T lymphocytes, with a marked migratory phenotype and an increase in depleted γδ lymphocytes. Conclusions: In the literature, there are few data on the LAG3, TIM3 and TIGIT expression in melanoma, therefore, this study may be able to contribute in this regard. LAG 3 is the highest of all the immunocheckpoints analyzed. Further studies will be needed to fully understand the function of these molecules in order to develop new immunotherapy protocols. In particular, the impact of neutralizing LAG3 with certain inhibitors should be further studied to understand the functional role of LAG3 in anti-PD1 resistant patients.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Immunocheckpoint"

1

Moerdler, Scott, and Xingxing Zang. PD-1/PDL-1 Inhibitors as Immunotherapy for Ovarian Cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0010.

Full text
Abstract:
Programmed death 1 (PD-1), a member of the B7-CD28 immunoglobulin superfamily, and its ligands PD-L1/PD-L2 inhibit T-cell activation. They also play a key role in the tumor microenvironment, allowing for cancer immune escape. PD-1 is induced on a variety of immune cells, including tumor-infiltrating lymphocytes (TILs), while PD-L1 is found on many types of solid tumors including ovarian cancer and some TILs. The use of immunocheckpoint inhibitors like anti-PD-1 and anti-PD-L1 therapies has been shown to reactivate the immune system to attack tumor cells. Ovarian cancers have been shown to be responsive to anti-PD-1 and anti-PD-L1 therapies, though immunocheckpoint inhibitors are not enough. Current research is evaluating combination therapies to improve response rates.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Immunocheckpoint"

1

Fujimoto, Nobukazu. "Immunocheckpoint Blockade in Malignant Pleural Mesothelioma." In Asbestos-related Diseases. IntechOpen, 2020. http://dx.doi.org/10.5772/intechopen.89116.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Matsuda, Asako, and Nobukazu Fujimoto. "Immunotherapy in Malignant Pleural Mesothelioma." In Advances in Precision Medicine Oncology. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.95823.

Full text
Abstract:
Malignant pleural mesothelioma (MPM) is an extremely aggressive plural malignancy mainly caused by asbestos exposure. Basic research about the immune suppressive tumor microenvironment in MPM has suggested that MPM might be a good candidate for immune therapy. Immunocheckpoint inhibitors have shown some promising results. A phase Ib trial with pembrolizumab, an antibody specific for the programmed cell death 1 protein (anti-PD-1), showed efficacy in patients with programmed death-ligand 1 (PD-L1)-positive MPM. Among 25 patients tested, 5 patients (20%) achieved a partial response. A Japanese group evaluated the efficacy and safety of nivolumab, an anti-PD-L1 antibody, for patients with advanced MPM in a phase II study. Ten (29%) patients showed an objective response. Based on those results, nivolumab was approved in Japan for unresectable recurrent MPM. A phase III randomized study was conducted to compare nivolumab plus ipilimumab to platinum doublet chemotherapy as a first-line therapy in unresectable MPM. The primary endpoint, overall survival (OS), was significantly improved in the nivolumab plus ipilimumab group. Cellular therapies and cancer vaccines are limited by many challenges; therefore, improvements to overcome these difficulties are urgently warranted. Further research is needed, including large-scale clinical trials, to clarify the utility and safety of immunotherapy in MPM.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Immunocheckpoint"

1

Mondello, Patrizia, Matt Teater, Lorena Fontan, Matthew Durant, Elisa de Stanchina, Giorgio Inghirami, Michael Green, and Ari Melnick. "Abstract 797: Targeting HDAC3 reactivates immunosurveillance and enhances immunocheckpoint activity in B-cell lymphoma." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-797.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Liu, Jia, Jia Bo Zheng, Chau Wei Wong, Xiao-jing Luo, Ze-xian Liu, Huai-Qiang Ju, and Rui-hua Xu. "IDDF2020-ABS-0118 Long non-coding RNA LRTIS regulates MLL1-mediated immunocheckpoint remodelling in esophageal squamous cell carcinoma." In Abstracts of the International Digestive Disease Forum (IDDF), 22–23 November 2020, Hong Kong. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2020. http://dx.doi.org/10.1136/gutjnl-2020-iddf.3.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Immunocheckpoint"

1

Jin, Yuanyang, and Zhimin Suo. Immunocheckpoint inhibitors for advanced gastric cancer or gastroesophageal junction cancer with different microsatellite stability: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2022. http://dx.doi.org/10.37766/inplasy2022.10.0106.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Immunocheckpoint' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography